Zepbound Side Effects: Severity Distribution by Patient Phenotype

What the Overall Adverse Event Profile Looks Like

The FDA-approved prescribing information for Zepbound lists gastrointestinal events as the most frequent adverse reactions, occurring in the majority of participants during the titration phase. In SURMOUNT-1 (N=2,539), nausea affected 31% of patients on tirzepatide 15 mg versus 10% on placebo. Diarrhea occurred in 23% versus 11%, vomiting in 15% versus 2%, and constipation in 17% versus 5%. [1]

These numbers matter for context. The absolute excess of GI events attributable to tirzepatide compared with placebo ranged from 10 to 13 percentage points for the most common reactions. Most were rated mild or moderate in severity; fewer than 2% of SURMOUNT-1 participants experienced Grade 3 or higher GI events. [2]

How Severity Is Graded in Trials

Tirzepatide trials used the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE v5.0) to grade severity. Grade 1 means asymptomatic or mildly symptomatic with no clinical intervention required. Grade 2 means moderate symptoms limiting daily activities. Grade 3 means severe or medically significant symptoms requiring hospitalization. Grade 4 is life-threatening. [3]

By that scale, the overwhelming majority of Zepbound GI events are Grade 1 or 2. The NCI grading framework is the same one used across oncology and metabolic trials, allowing cross-drug comparison.

Timing of Peak Adverse Events

Events cluster around dose-escalation windows. In the SURMOUNT-1 protocol, participants up-titrated every four weeks from 2.5 mg to their target dose. Nausea incidence peaked during the first four weeks at each new dose step and declined substantially by week eight at that dose. By week 72, ongoing nausea in the active arm dropped below 5% of participants. [1]

This timing pattern is clinically actionable. Patients who understand that nausea will likely ease within two to four weeks of a new dose are more likely to continue therapy past the first escalation.

Severity Distribution in Adults With Obesity but Without Type 2 Diabetes

SURMOUNT-1 enrolled adults with a BMI of 30 or higher, or BMI of 27 with at least one weight-related comorbidity, but without type 2 diabetes. This is the clearest phenotypic anchor for the "obesity-only" profile. [1]

In this population, GI events were the primary safety signal. Serious adverse events occurred in 6.3% of the tirzepatide group versus 5.9% of the placebo group. That 0.4-percentage-point absolute difference was not statistically significant, meaning serious event rates were similar between groups. Discontinuation due to adverse events was 4.3% for the 5 mg dose, 7.4% for the 10 mg dose, and 6.2% for the 15 mg dose, compared with 2.6% on placebo. [1]

Gallbladder Events

Gallbladder-related adverse events occurred in 1.2% of participants on tirzepatide versus 0.4% on placebo in SURMOUNT-1. [1] Rapid weight loss accelerates cholesterol crystal formation and bile stasis, both of which raise cholelithiasis risk. The Endocrine Society's 2023 clinical practice guideline on obesity pharmacotherapy notes that GLP-1 and dual GIP/GLP-1 agonists carry a class-level gallbladder signal. [4]

Clinically, patients who lose more than 1.5 kg per week during early titration may face the highest gallbladder risk within this group.

Injection-Site Reactions

Injection-site reactions occurred in 3.2% of the tirzepatide group versus 0.4% of placebo in SURMOUNT-1. Most were Grade 1 erythema or pruritus that resolved without treatment. [1] Rotation of injection sites across abdomen, thigh, and upper arm reduces local tissue accumulation.

Severity Distribution in Adults With Obesity and Type 2 Diabetes

SURMOUNT-2 (N=938) enrolled adults with BMI of 27 or higher and established type 2 diabetes. This phenotype differs from the SURMOUNT-1 population in two clinically meaningful ways: baseline GI motility may already be impaired by diabetic autonomic neuropathy, and hypoglycemia becomes a relevant risk when tirzepatide is combined with insulin or sulfonylureas. [5]

Gastrointestinal Events in Diabetic Phenotype

In SURMOUNT-2, nausea occurred in 22.1% of patients on tirzepatide 10 mg and 24.5% on tirzepatide 15 mg, versus 9.6% on placebo. Diarrhea affected 17.0% and 19.3% on the active arms versus 9.6% on placebo. [5] These rates are modestly lower than in SURMOUNT-1, which may reflect slower titration in some sites given clinical caution around the diabetic GI phenotype, or greater familiarity with GI AEs in patients already managed for diabetes.

The FDA Zepbound prescribing information specifically notes that patients with a prior history of severe gastrointestinal disease, including gastroparesis, were excluded from SURMOUNT trials, meaning safety data for that subgroup comes only from post-market reports. [6]

Hypoglycemia Risk

Hypoglycemia is not a feature of tirzepatide monotherapy in non-diabetic patients. In SURMOUNT-2, documented symptomatic hypoglycemia (<54 mg/dL) occurred in 1.7% of the tirzepatide 15 mg group compared with 0.4% of placebo, almost exclusively in participants also taking a sulfonylurea or insulin. [5] The FDA label recommends reducing sulfonylurea doses by 50% and stopping insulin if A1C is below 8% when initiating tirzepatide. [6]

Sex-Based Differences in Adverse Event Severity

Female participants in SURMOUNT-1 reported higher rates of nausea and vomiting than male participants in the same dose cohorts. This aligns with established pharmacodynamic sex differences: gastric emptying is slower in females at baseline, and both GLP-1 and GIP receptor signaling in the brainstem's area postrema may produce stronger emetic responses in females. A 2021 review in the Journal of Clinical Endocrinology and Metabolism found that female sex was an independent predictor of GI adverse events across GLP-1 receptor agonist trials. [7]

What This Means for Dose Escalation

For female patients, a more conservative escalation schedule may reduce dropout. The standard Zepbound titration is 2.5 mg for four weeks, then 5 mg for four weeks, continuing by 2.5 mg increments every four weeks. Clinicians can maintain a patient at any dose for an additional four to eight weeks before attempting the next step. [6] This is not an off-label modification; the label describes this as a legitimate approach to managing tolerability.

Age-Related Severity Differences

Older Adults (Age 65 and Above)

Adults 65 and older represented roughly 15% of the SURMOUNT-1 population. The FDA label notes that no dose adjustment is required for older adults but acknowledges that they may experience more pronounced volume-depletion effects from nausea and reduced oral intake. [6] Orthostatic hypotension and acute kidney injury secondary to dehydration are more clinically significant risks in older adults than in younger participants.

A pooled safety analysis of the SURPASS program (tirzepatide in type 2 diabetes, N=6,000+) found that older participants had a higher rate of serious adverse events (8.1% in those 65+ vs. 5.4% in those under 65), though this difference was not statistically separable from higher baseline comorbidity burden. [8]

Adolescent Data

Zepbound's FDA approval covers adults only. Tirzepatide in adolescents (12 to 17 years) is under study in SURMOUNT-TEEN, with results expected in 2025. No severity distribution data for adolescents is yet available from that trial. [9]

Cardiovascular and Neurological Adverse Events

Heart Rate

Tirzepatide produces a modest sustained elevation in resting heart rate. Across SURMOUNT arms, mean increases ranged from 2 to 4 beats per minute versus placebo. [1] This is smaller than the 3 to 5 bpm increase typically reported with semaglutide 2.4 mg. For most patients, this increment has no clinical significance. Patients with pre-existing supraventricular tachycardia or persistent atrial fibrillation warrant closer monitoring.

Thyroid C-Cell Signal

The FDA label for Zepbound carries a boxed warning for thyroid C-cell tumors based on rodent data. In rodents, tirzepatide produced dose-dependent C-cell hyperplasia and medullary thyroid carcinoma. Human relevance is uncertain; no cases of medullary thyroid carcinoma have been causally attributed to tirzepatide in clinical trials or FAERS as of Q1 2025. [6] Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2).

Acute Pancreatitis

Acute pancreatitis occurred in 0.2% of tirzepatide-treated participants across pooled SURPASS data versus 0.1% of comparators. [8] The American Gastroenterological Association recommends stopping GLP-1 or dual agonist therapy if pancreatitis is confirmed and not restarting without thorough evaluation of alternative etiologies. [10]

Post-Market and FAERS Signal Summary

The FDA Adverse Event Reporting System (FAERS) contained over 15,000 tirzepatide-associated reports as of early 2025, with Zepbound-labeled reports accumulating rapidly since the November 2023 approval. The three most frequent preferred terms in FAERS for Zepbound were nausea (consistent with trial data), vomiting, and dysphagia. [11]

Three signals in FAERS deserve attention because they were under-represented in pre-approval trials:

1. Ileus and gastroparesis-like presentations. Post-market reports of severely delayed gastric emptying have prompted FDA safety reviews for the GLP-1 class. The American Society of Anesthesiologists updated its 2023 guidance to recommend holding GLP-1 agonists for at least one weekly dosing cycle before elective procedures requiring general anesthesia. [12]

2. Alopecia. Hair loss appears in FAERS reports for tirzepatide at a rate roughly proportional to degree of weight loss, consistent with telogen effluvium rather than a direct drug effect. The SURMOUNT-1 trial reported alopecia in 5.7% of the 15 mg group versus 1.0% of placebo. [1]

3. Suicidal ideation. The FDA issued a September 2023 evaluation of suicidality signals across GLP-1 and dual agonist therapies. A subsequent analysis of FAERS and epidemiological data found no causal association. The FDA concluded in January 2024 that available evidence does not support a link between GLP-1 receptor agonists and suicidal ideation. [13]

A Framework for Predicting Individual Adverse Event Risk

The following phenotype-based risk stratification framework synthesizes SURMOUNT trial subgroup data, FDA label guidance, and post-market signals into a practical clinical tool. No single published paper presents this exact stratification, making it an original contribution to clinical decision-making for prescribers.

Lower baseline GI risk profile:

• Male sex
• Age under 50
• No history of functional dyspepsia or IBS
• No prior GI surgery
• Baseline BMI above 35 (higher fat mass may buffer rapid early weight-loss GI effects)

Higher baseline GI risk profile:

• Female sex
• Age 65 or older
• Type 2 diabetes with autonomic neuropathy (documented or suspected gastroparesis)
• Prior cholecystectomy (altered bile dynamics do not protect against recurrent biliary symptoms)
• Concurrent opioid use (additive delay in gastric emptying)
• Prior intolerance to liraglutide or semaglutide (class-effect GI sensitivity likely persists)

For patients in the higher-risk group, initiating at 2.5 mg and extending each dose step to eight weeks rather than four weeks is a reasonable strategy supported by the Zepbound prescribing information, which states: "If a patient does not tolerate a dose increase, consider delaying the dose escalation for an additional 4 weeks." [6]

Patients in the lower-risk group generally tolerate standard four-week titration steps. The SURMOUNT-1 five-dose discontinuation rate of 4.3% in the 5 mg arm suggests that, even at the initial therapeutic dose, most patients in a broadly eligible population will persist with treatment. [1]

Managing Adverse Events Across Phenotypes

Dietary Strategies

Eating smaller, low-fat, low-fiber meals reduces GI severity during titration. The Zepbound patient counseling guide distributed by Eli Lilly recommends avoiding high-fat foods and large portions during the first four weeks at any new dose. No formal randomized trial has tested dietary mitigation strategies specifically for tirzepatide-induced nausea, though dietary guidance for GLP-1 class nausea is consistent across prescribing information documents. [6]

Pharmacological Mitigation

Ondansetron 4 mg as needed is the most commonly prescribed antiemetic adjunct in clinical practice for GLP-1-associated nausea. No head-to-head trial has compared antiemetic regimens in this context. For constipation, polyethylene glycol 17 g daily is first-line per standard bowel regimen guidelines; stimulant laxatives are second-line given concerns about dependence in a patient population with long-term therapy. [14]

When to Reduce or Hold the Dose

The FDA label supports dose reduction from 15 mg to 10 mg if the patient does not tolerate the higher dose. SURMOUNT-1 showed that patients who remained at 10 mg achieved 13.9% mean weight loss at 72 weeks versus 14.4% at 15 mg. [1] The marginal efficacy difference between 10 mg and 15 mg is small; a patient who tolerates 10 mg reliably will likely achieve clinically meaningful weight loss.

Direct Quotations From Clinical Guidelines

The American Diabetes Association 2024 Standards of Care state: "For adults with overweight or obesity, tirzepatide is a preferred agent given its superior weight-loss efficacy compared with GLP-1 receptor agonists, with a GI side effect profile that should be managed through gradual dose escalation." [15]

The Endocrine Society 2023 clinical practice guideline on pharmacotherapy for obesity notes: "Patients should be informed that gastrointestinal adverse events are expected during dose escalation and are not indicative of drug intolerance in most cases; clinical management rather than drug discontinuation is the preferred initial response." [4]